文献速递药物不良反应与药物警戒

利奈唑胺与QT间期延长风险:FDA不良事件报告系统的药物警戒研究

Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System.
PubMed 文献 · Br J Clin Pharmacol · 2022-11-23

共获取6738份利奈唑胺为主要或次要可疑药物的不良事件报告,其中192份为心电图QT延长,报告比值比(ROR)为26.1(95%CI 22.6-30.2)。结核患者使用利奈唑胺时QT延长的报告率更高,比值比为330.0(95%CI 223.1-488.1)。

要点

  • 利奈唑胺与QT间期延长存在关联,ROR为26.1(95%CI 22.6-30.2)。
  • 结核患者使用利奈唑胺时QT延长报告率更高,比值比330.0(95%CI 223.1-488.1)。
  • 长QT综合征ROR 14.2(95%CI 7.1-28.5),尖端扭转型室速ROR 3.2(95%CI 1.3-7.6)。

核心结论

  • 研究显示利奈唑胺与QT间期延长存在关联。
  • 在结核患者报告中,使用利奈唑胺时QT延长的发生率更高。

研究设计与样本

  • 共获取6738份利奈唑胺为主要或次要可疑药物的不良事件报告,其中192份为心电图QT延长。

主要发现

  • QT延长的报告比值比(ROR)为26.1(95%CI 22.6-30.2)。
  • 长QT综合征8份报告,ROR 14.2(95%CI 7.1-28.5)。
  • 尖端扭转型室速5份报告,ROR 3.2(95%CI 1.3-7.6)。
  • 室性心动过速5份报告,ROR 1.9(95%CI 0.8-4.5)。
  • 结核患者使用利奈唑胺时QT延长报告率更高,比值比330.0(95%CI 223.1-488.1);有无结核患者中利奈唑胺相关QT延长的比值比分别为4.2(95%CI 3.4-5.3)和1.2(95%CI 0.8-1.6)。

临床怎么用

  • 临床使用利奈唑胺时应关注QT间期延长风险,尤其是结核患者。
  • 对使用利奈唑胺的患者,可考虑监测心电图QT间期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Few studies have investigated linezolid (LZD)-associated cardiotoxicity. This study explored the potential association between LZD and QT interval prolongation. METHODS: Adverse event reports of QT interval prolongation associated with LZD from the Food and Drug Administration Adverse Event Reporting System from January 2013 to December 2021 were analysed and the reporting odds ratio (ROR) with 95% confidence intervals were calculated. RESULTS: A total of 6738 adverse event reports of LZD as the primary and secondary suspected drug were obtained from the database, including 192 reports with electrocardiogram QT prolonged (QTp), and the ROR value was 26.1 (95% CI = 22.6-30.2). There were 8 reports of long QT syndrome, ROR 14.2 (95% CI = 7.1-28.5); 5 reports of torsade de pointes, ROR 3.2 (95% CI = 1.3-7.6); and 5 reports of ventricular tachycardia, ROR 1.9 (95% CI = 0.8-4.5). Subgroup analysis revealed that patients with tuberculosis treated with LZD had a higher reporting rate among all QTp reports, exhibiting an odds ratio of 330.0 (95% CI = 223.1-488.1). The odds ratios of QTp associated with LZD treatments in patients with and without tuberculosis were 4.2 (95% CI = 3.4-5.3) and 1.2 (95% CI = 0.8-1.6), respectively. CONCLUSION: The study showed an association between LZD and QT interval prolongation. In the report on patients with tuberculosis, the incidence of QTp was higher when treated with LZD.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Shao H, Shi D, Dai Y, et al. Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System. Br J Clin Pharmacol. 2022. PMID: 36346345. doi:10.1111/bcp.15587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。